Samsca (Tolvaptan) Patent Expiration, LOE Window & CMS Spending

Samsca (Tolvaptan) by Otsuka Pharmaceutical: FDA Orange Book core substance LOE 2026-09-01 (last listed 2030-04-07), 9 AB generics, $9.4M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOtsuka Pharmaceutical
FDA Application & PathwayN022275 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-09-01
Last Listed Patent or Exclusivity Date2030-04-07
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors9
2024 CMS Total Public Spend$9.4M
2024 Medicare Part D Spend$8.7M
2024 Medicaid Spend$633K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.